iTeos Therapeutics, Inc. financial data

Location
Watertown, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2025 - 06 Aug 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1143% % -30%
Debt-to-equity 18% % 24%
Return On Equity -36% % -95%
Return On Assets -30% % -90%
Operating Margin -456% % 62%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44,205,398 shares 21%
Common Stock, Shares, Outstanding 38,271,682 shares 4.8%
Entity Public Float $493,900,000 USD
Common Stock, Value, Issued $44,000 USD 19%
Weighted Average Number of Shares Outstanding, Basic 43,564,573 shares 9.7%
Weighted Average Number of Shares Outstanding, Diluted 43,564,573 shares 9.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD -100%
Research and Development Expense $160,523,000 USD 24%
General and Administrative Expense $45,084,000 USD -10%
Operating Income (Loss) $221,942,000 USD -53%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $190,045,000 USD -85%
Income Tax Expense (Benefit) $12,367,000 USD 119%
Net Income (Loss) Attributable to Parent $202,412,000 USD -87%
Earnings Per Share, Basic -4 USD/shares -56%
Earnings Per Share, Diluted -4 USD/shares -56%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $207,820,000 USD -17%
Assets, Current $528,993,000 USD -16%
Property, Plant and Equipment, Net $5,175,000 USD -3%
Operating Lease, Right-of-Use Asset $5,129,000 USD -6.7%
Other Assets, Noncurrent $898,000 USD 14%
Assets $623,083,000 USD -17%
Accounts Payable, Current $6,249,000 USD -43%
Employee-related Liabilities, Current $23,774,000 USD 349%
Accrued Liabilities, Current $943,000 USD -96%
Liabilities, Current $70,274,000 USD 103%
Operating Lease, Liability, Noncurrent $3,612,000 USD -15%
Liabilities $129,282,000 USD 47%
Accumulated Other Comprehensive Income (Loss), Net of Tax $16,190,000 USD 2.2%
Retained Earnings (Accumulated Deficit) $123,123,000 USD -255%
Stockholders' Equity Attributable to Parent $493,801,000 USD -26%
Liabilities and Equity $623,083,000 USD -17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $33,764,000 USD -4.2%
Net Cash Provided by (Used in) Financing Activities $32,000 USD 45%
Net Cash Provided by (Used in) Investing Activities $47,692,000 USD
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 38,271,682 shares 4.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $14,419,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $208,139,000 USD -17%
Deferred Tax Assets, Valuation Allowance $97,331,000 USD 31%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure -16%
Deferred Tax Assets, Gross $99,276,000 USD 30%
Operating Lease, Liability $5,128,000 USD -7%
Payments to Acquire Property, Plant, and Equipment $101,000 USD -89%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $202,042,000 USD -81%
Lessee, Operating Lease, Liability, to be Paid $5,573,000 USD -8%
Property, Plant and Equipment, Gross $11,225,000 USD 14%
Operating Lease, Liability, Current $1,516,000 USD 19%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,599,000 USD 9%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,108,000 USD -26%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $445,000 USD -18%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,089,000 USD 12%
Deferred Tax Assets, Operating Loss Carryforwards $17,827,000 USD -18%
Unrecognized Tax Benefits $48,790,000 USD 13%
Lessee, Operating Lease, Liability, to be Paid, Year Four $838,000 USD 6.6%
Operating Lease, Payments $1,612,000 USD 14%
Additional Paid in Capital $633,070,000 USD 5.3%
Deferred Tax Assets, Net of Valuation Allowance $1,945,000 USD 5.6%
Share-based Payment Arrangement, Expense $27,131,000 USD -8.3%